Agena Announces MassARRAY Commercial Partnership Agreement With Dian For China Clinical Laboratory Market

SAN DIEGO, July 10, 2018 /PRNewswire/ -- Agena Biosciences announced today that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd ("Dian"), one of China's largest independent medical laboratories providers. The strategic agreement will enable Dian to promote and broadly commercialize Agena's MassARRAY® System and DNA testing applications and products throughout their network of laboratories in China.

Headquartered in Hangzhou, China, Dian's business model provides a comprehensive "Product + Service" approach for medical institutions. This broad market approach ranges from providing third party diagnostic testing from their independent laboratory network, to providing a centralized procurement service of instruments and reagents for hospitals interested in establishing their own laboratories. The MassARRAY System has been selected by Dian as the platform of choice for their molecular genetic testing.

"The flexibility, high throughput, and low operational cost of the MassARRAY System is ideal for the needs of the rapidly growing diagnostic test market in China," said HaiBin Chen, the chairman of Dian Diagnostics. "It supports our business model as we expect that the simple workflow combined with MassARRAY's robust analytical performance will allow rapid expansion through our laboratory network, while also enabling us to help new laboratories establish their own programs."

"Dian is a well-positioned leader in the clinical lab market and we feel honored to have been chosen by them," said Peter Dansky, Chief Executive Officer at Agena Bioscience. "With their extensive network of laboratories and expertise in bringing up new diagnostic tests, they are an important partner and will further spur the growth of our technology in China."

About Agena Bioscience
Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

About Zhejiang Dian Diagnostics Co., Ltd.
Zhejiang Dian Diagnostics, Co., Ltd. Engages in the sale, outsourcing, research and development of medical diagnostic products and services for general and specialized hospitals, community health service centers, medical centers, and disease prevention and control centers. Dian was founded 2001 and is now one of China's largest chains of independent medical laboratories. The company has established more than 30 independent laboratories throughout the country to provide "product + service" integrated total solutions for medical diagnosis to more than 12,000 medical institutions in China. Dian is headquartered in Hangzhou, China. For more information, visit www.diandiagnostics.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/agena-announces-massarray-commercial-partnership-agreement-with-dian-for-china-clinical-laboratory-market-300678593.html

SOURCE Agena Bioscience

 

Back to news